CoChat

Mesalazine (5‐aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea‐predominant irritable bowel syndrome

Open access
Andrews, C. N., Griffiths, T. A., Kaufman, J., Vergnolle, N., Surette, M. G., Rioux, K. P. · 2011 · Alimentary Pharmacology & Therapeutics
Cited by 97

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Aliment Pharmacol Ther 2011; 34: 374–383 Summary: Background Imbalances in gut luminal bacteria may contribute to the pathogenesis of irritable bowel syndrome (IBS). Aim To explore select bacteriological and anti‐inflammatory effects of mesalazine (mesalamine; 5‐aminosalicylic acid or 5ASA) and their relation to potential therapeutic effects in IBS. Methods Prospective pilot study of 12 women with diarrhoea‐predominant IBS. Patients received oral mesalazine (1.5 g b.d.) for 4 weeks followed by a 4‐week washout phase. Molecular profiling of stool bacterial communities and IBS symptoms were assessed before, during and after mesalazine treatment. Colonic mucosal biopsies were assessed for proteolytic activity. Qualitative and quantitative effects of mesalazine on stool microbiota, mucosal proteolytic activity and IBS symptoms were assessed. Results Faecal bacteria decreased by 46% on mesalazine treatment (P = 0.014), but returned to baseline during washout. Firmicutes and Bacteroidetes represented 95% of identified phylotypes, with a trend towards an increase in the proportion of Firmicutes at week 4 in symptomatic responders [median (IQR) 14% (49) increase] compared with nonresponders [median 5% (11) decrease, P = 0.088]. Rectosigmoid mucosal proteolytic activity did not change between baseline and treatment [median 23.2 (17.9) vs. 19.5 (46.7) mU activity/mg tissue, P = 0.433]. Eight of 12 (67%) patients responded favourably to mesalazine based on a global relief questionnaire, with significant decreases in days with discomfort and increases in bowel movement satisfaction. Conclusions Mesalazine treatment is associated with a decrease in faecal bacteria abundance and rebalancing of the major constituents of the microbiota. Further study of the bacteriological and anti‐inflammatory properties of mesalazine in IBS is warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2011.04732.x

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 97

Metadata

Authors
Andrews, C. N., Griffiths, T. A., Kaufman, J., Vergnolle, N., Surette, M. G., & Rioux, K. P.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2011-06-14
Volume
34
Issue
3
Pages
374-383
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W1549133315
Cited by
97
References
18
FWCI
6.70
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mesalazine (5‐aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea‐predominant irritable bowel syndrome. https://app.cochat.ai/papers/10.1111/j.1365-2036.2011.04732.x
The paper
Andrews, C. N., Griffiths, T. A., Kaufman, J., Vergnolle, N., Surette, M. G., & Rioux, K. P. (2011). Mesalazine (5‐aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea‐predominant irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2011.04732.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.